Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita, Japan.
Clin Chem Lab Med. 2011 Jun;49(6):959-66. doi: 10.1515/CCLM.2011.152. Epub 2011 Mar 24.
Hepatocellular carcinomas (HCC) are the fifth most common tumor type and the third most common cause of cancer-related death worldwide. Some tumor markers for HCC, such as α-fetoprotein and des-γ-carboxyprothrombin, are used clinically. Recent advances in proteomics and glyco-proteomics might provide various types of novel tumor markers for HCC. While the clinical availability of these tumor markers is important, the molecular mechanisms underlying the production of tumor markers requires further clarification. Our group has investigated the glycobiology of tumor markers. In this review, we describe the impact of novel HCC markers and their possible implications for clinical use.
肝细胞癌 (HCC) 是全球第五大常见肿瘤类型,也是癌症相关死亡的第三大常见原因。一些 HCC 的肿瘤标志物,如甲胎蛋白和去γ-羧基凝血酶原,已在临床上使用。蛋白质组学和糖蛋白质组学的最新进展可能为 HCC 提供各种类型的新型肿瘤标志物。虽然这些肿瘤标志物的临床可用性很重要,但肿瘤标志物产生的分子机制仍需要进一步阐明。我们小组研究了肿瘤标志物的糖生物学。在这篇综述中,我们描述了新型 HCC 标志物的影响及其对临床应用的可能意义。